Loading
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Latest quote
$1.36
−$0.05 · -3.55%
After-hours
$1.36
$0.00 · 0.00%
Oct 8, 7:44 PM ET
Regular session · ET · Market data may be delayed.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Day range
Current $1.36
52-week range
Current $1.36
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
77
Undervalued
Sentiment
28
Bearish
Risk
76
High Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Day range
Current $1.36
52-week range
Current $1.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 70.39M USD | 59.35M USD | 70.14M USD | 138.59M USD | 104.75M USD |
| Cost of goods sold | 9.34M USD | 16.29M USD | 12.81M USD | 38.03M USD | 22.21M USD |
| Gross profit | 61.05M USD | 43.06M USD | 57.33M USD | 100.56M USD | 82.55M USD |
| Research and development | 52.31M USD | 46.26M USD | 58.89M USD | 80.1M USD | 55.92M USD |
| Selling, general, and administrative | 47.07M USD | 55.15M USD | 53.25M USD | 52.17M USD | 49.32M USD |
| Operating expenses | 99.38M USD | 101.58M USD | 125.4M USD | 135.44M USD | 105.24M USD |
| Interest income | 2.63M USD | 3.67M USD | 4.17M USD | 1.44M USD | 459K USD |
| Interest expense | 4.81M USD | — | — | — | — |
| Depreciation and amortization | 5.25M USD | 4.95M USD | 9.92M USD | 10.25M USD | 5.95M USD |
| Operating income | −38.33M USD | −58.52M USD | −68.07M USD | −34.88M USD | −22.7M USD |
| Net income | −43.97M USD | −65.28M USD | −76.24M USD | −33.59M USD | −21.28M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.00
488.24% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.23M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM3.62M0.00%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF1.54M0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO1.14M0.01%14.04B USD0.24%$353.47-0.53%
iShares Biotechnology ETFIBB1.09M0.01%10.41B USD0.44%$200.48-1.41%
Vanguard Russell 2000 ETFVTWO846.59K0.00%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC449.94K0.03%1.33B USD0.60%$182.79-0.31%
Fidelity Enhanced Small Cap ETFFESM252.31K—6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
